Tag Archives: NYSE:XON

Analysts Offer Insights on Healthcare Companies: Intrexon (NYSE: XON) and Puma Biotechnology (NYSEArca: PBYI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intrexon (NYSE: XON) and Puma Biotechnology (NYSEArca: PBYI). Intrexon (NYSE: XON) In a report released today, Robert Breza from Northland Securities reiterated a

A Director at Intrexon is Exercising Options

Yesterday, a Director at Intrexon, Steven Frank, exercised options of Intrexon for $23.51K. The options were close to expired and Steven Frank retained stocks. Following this transaction Steven Frank’s holding in the company was increased by 4.94% to a total

Northland Securities Thinks Intrexon’s Stock is Going to Recover

Northland Securities analyst Robert Breza reiterated a Buy rating on Intrexon (NYSE: XON) yesterday and set a price target of $21. The company’s shares closed yesterday at $11.81, close to its 52-week low of $11.80. According to TipRanks.com, Breza is

Northland Securities Reaffirms Their Buy Rating on Intrexon

Northland Securities analyst Robert Breza reiterated a Buy rating on Intrexon (NYSE: XON) yesterday and set a price target of $27. The company’s shares opened today at $20.28. According to TipRanks.com, Breza is a 4-star analyst with an average return

Intrexon Gets a Buy Rating from Northland Securities

Northland Securities analyst Robert Breza reiterated a Buy rating on Intrexon (NYSE: XON) today and set a price target of $30. The company’s shares opened today at $21.65. According to TipRanks.com, Breza is a 3-star analyst with an average return

The SVP, Finance of Intrexon (NYSE: XON) is Buying Shares

Today, the SVP, Finance of Intrexon (NYSE: XON), Joel Liffman, bought shares of XON for $243.2K. This recent transaction increases Joel Liffman’s holding in the company by 5.67% to a total of $4.26 million. In addition to Joel Liffman, 2